Events – Adragos Pharma https://adragos-pharma.com Your Global CDMO Fri, 10 Jul 2026 12:49:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.3 https://adragos-pharma.com/wp-content/uploads/2024/04/cropped-Adragos-Pharma-Symbol-2024-32x32.png Events – Adragos Pharma https://adragos-pharma.com 32 32 Webinar: De-Risking Sterile Fill-Finish from Clinical to Commercial | Adragos Pharma https://adragos-pharma.com/webinar-de-risking-sterile-fill-finish-from-clinical-to-commercial-adragos-pharma/ https://adragos-pharma.com/webinar-de-risking-sterile-fill-finish-from-clinical-to-commercial-adragos-pharma/#respond Thu, 09 Jul 2026 10:45:47 +0000 https://adragos-pharma.com/?p=26202

De-Risking Sterile Fill-Finish from Clinical to Commercial

How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success.

Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, technology transfer, quality expectations and supply continuity all need the right technical and operational support. Join Adragos Pharma for a practical webinar designed for CMC, outsourcing, MSAT, technical operations and external manufacturing teams looking to reduce risk across the sterile product lifecycle.

Is this your programme?

This webinar is designed for teams working on sterile products where timelines, quality and supply reliability matter. It is especially relevant for:

  • CMC and pharmaceutical development teams
  • Outsourcing and external manufacturing leaders
  • MSAT and technical operations teams
  • Sterile manufacturing and fill-finish leads
  • Technology transfer and industrialisation teams
  • Procurement and supply chain decision-makers
  • Project and programme managers supporting clinical-to-commercial progression

The Challenge

Sterile manufacturing is where complexity becomes operational

Bringing sterile products to market requires more than capacity. Each stage introduces potential risk: process transfer, scale-up, lyophilisation, aseptic control, inspection, packaging and commercial supply planning.

πŸ”

Process Transfer Risk

Delays are not always caused by the science. Unclear transfer models and insufficient CDMO flexibility create execution challenges that slow programmes down.

❄

Lyophilisation Complexity

Scale-up from clinical to commercial demands deep technical expertise, robust cycle development and rigorous qualification β€” up to ~70,000 vials per batch.

🏭

Aseptic Control at Scale

Aseptic manufacturing requires consistent quality governance, controlled environments, RABS technology, audit readiness and compliant fill-finish execution.

πŸ“¦

Supply Continuity

Manufacturing partners must support the full journey β€” from clinical development to commercial supply β€” with flexibility and long-term operational commitment.

πŸ“‹

Regulatory CMC Readiness

CMC submissions, stability studies, analytical validation and multi-authority compliance add significant complexity across every product stage.

🌐

Clinical-to-Commercial Continuity

Bridging clinical batches to commercial supply requires an integrated CDMO partner with depth across dosage forms β€” not disconnected service modules.

The right CDMO partner can help reduce these risks by combining technical depth, quality-driven execution and a network able to adapt as your product needs evolve β€” from first GMP batch to high-volume commercial supply.



Practical insights to help reduce programme risk

During the webinar, Adragos Pharma experts will share how an integrated sterile CDMO model can support customers across key stages of the product lifecycle. You will learn how to:

  • Identify what to look for in a sterile fill-finish CDMO partner
  • Reduce technical risk during lyophilisation qualification and scale-up
  • Improve speed and consistency through structured technology transfer
  • Integrate products into sterile manufacturing facilities with a clear execution model
  • Use a flexible sterile network to support clinical-to-commercial supply

Two practical case studies

Real-world examples of how Adragos Pharma experts approach sterile programme challenges, from qualification through to commercial execution.

Lyophilisation Qualification and Scale-Up

Learn how lyophilisation performance, product temperature mapping, sublimation behaviour and process robustness can be assessed to support scale-up from clinical to commercial manufacturing.

Product Integration into a Sterile Manufacturing Facility

Explore how a structured, site-independent approach to technology transfer can support faster, more consistent product integration across a CDMO network.

Adragos Pharma’s sterile manufacturing network combines aseptic fill-finish, lyophilisation, inspection, packaging and quality-driven execution across multiple sites.

Our sterile capabilities include prefilled syringes, liquid and lyophilised vials, ampoules, inspection, packaging and commercial manufacturing support. The Sterile Cluster brochure positions Adragos as a global integrated partner from clinical manufacturing to high-volume global supply.

With Maisons-Alfort and Jura as key sterile sites, Adragos Pharma is strengthening its ability to support customers with both commercial-scale execution and clinical-to-commercial flexibility.

Batch sizes from 30 to 1,500 L
Aseptic filling or terminal sterilisation process by heat

⟢

Clinical and small-scale commercial manufacturing
Sterile liquids, suspension, emulsion, viscous liquids and lyophilised
Glass vials size: 2R, 6R, 10R, 20R, 30R​

⟢

Manufacturing of PFS and vials supported by CIP/SIP and active RABS technologies.

PFS: 0,5 mL and 1 mL
Vials: 6R, 10R, 7 mL, 10 mL, 15 mL, 22 mL

⟢

Meet Our Speakers

Highly skilled and well-trained scientists focused on development.

Paul Marnat

Head of Tech Transfer, Maisons-Alfort

Paul Marnat is a pharmacist with more than 12 years of leadership experience in sterile pharmaceutical manufacturing, specialising in aseptic operations, GMP compliance, and technology transfer.
Over the course of his career, he has held key manufacturing leadership roles across several Sanofi injectable manufacturing sites, overseeing operations and delivering complex industrial projects, including aseptic process transfers and product launches.
Following the 2026 acquisition of Sanofi’s Maisons-Alfort injectable manufacturing site by Adragos Pharma, Paul has served as Head of Customer Service & Tech Transfer at Adragos Pharma.
He now leads customer-facing activities and technology transfer programmes, partnering closely with internal teams to deliver efficient product transfers and dependable fill-finish operations.

Guillaume Mollandin

Head of Engineering and PMO, Jura

Guillaume Mollandin is a microbiology engineer with more than 14 years of progressive leadership in pharmaceutical manufacturing and project management. He began his career advancing from Manufacturing Manager in aseptic filling and visual inspection to Head of Packaging Operations. In 2020 he joined another company as Head of Fill-Finish Operations. From 2021 to 2023 he led aseptic fill-finish process development and served as MSAT Head for a DPS growth project. Since November 2024, Guillaume has been Head of Engineering & Project Management (PMO) at Adragos Pharma’s Jura site, spearheading flexible, customer-focused fill-finish solutions.

Tobias SchlΓΆgl

Business Development Director

Tobias joined Adragos Pharma in February 2026 as Business Development Director and brings 20 years of experience in the pharmaceutical industry with profound know-how in sterile drug product manufacturing and pharmaceutical services. Working several years for Vetter Pharma, he held various positions including Quality Assurance, Project Management and, most recently, as a Business Development Manager. In addition, he was several years Head of Drug Product Manufacturing aseptic production at Boehringer Ingelheim.
At Adragos Pharma, Tobias is focusing on fill & finish services. In his role he also supports the sales and marketing team and helps broaden the expertise and network for small molecules and biologic products. He contributes with his understanding of production and quality, combined with the ability to translate complex technical topics into value-added solutions for partners and stakeholders.

Β 
]]>
https://adragos-pharma.com/webinar-de-risking-sterile-fill-finish-from-clinical-to-commercial-adragos-pharma/feed/ 0
Adragos at CPHI WW, Milan 2026 https://adragos-pharma.com/adragos-at-cphi-ww-milan-2026/ https://adragos-pharma.com/adragos-at-cphi-ww-milan-2026/#respond Tue, 16 Jun 2026 09:40:55 +0000 https://adragos-pharma.com/?p=25556

CPHI (Convention on Pharmaceutical Ingredients) is the leading global gathering for the pharmaceutical industry. It brings together research, development and manufacturing experts to forge partnerships that drive new therapies and innovations for patients everywhere. Covering the full supply chain, from raw materials to finished products. CPHI offers a unique platform for making vital connections and exploring the latest trends, technologies and challenges.

This year, Adragos is excited to return to CPHI. We invite you to connect with us at the event!

πŸ“… Date: October 6-8 2026
πŸ“Location: Fiero Milano in Italy

Booth Number: #10H25

What to Discuss With Us at Booth #10H25

Our full team is in Milan. Whether you are working on early-stage development, scaling sterile manufacturing, exploring non-sterile production or entering the Japanese market, we are ready for a technical conversation.

About Last Year CPHI in Frankfurt

]]>
https://adragos-pharma.com/adragos-at-cphi-ww-milan-2026/feed/ 0
Adragos Pharma at the 14th Antibody Industrial Symposium (AIS2026) β€” Montpellier, France https://adragos-pharma.com/adragos-pharma-at-the-14th-antibody-industrial-symposium-ais2026-montpellier-france/ https://adragos-pharma.com/adragos-pharma-at-the-14th-antibody-industrial-symposium-ais2026-montpellier-france/#respond Thu, 28 May 2026 13:29:21 +0000 https://adragos-pharma.com/?p=25408

Adragos Pharma is pleased to confirm its participation in the 14th Antibody Industrial Symposium (AIS2026), taking place in Montpellier, France. Organised by MabDesign and MabImprove, AIS2026 brings together leading players across the antibody and biologics value chain β€” from discovery through to commercial manufacturing. As a European Contract Development and Manufacturing Organisation (CDMO) with dedicated aseptic fill-and-finish capabilities for biological products, we look forward to connecting with biotech innovators, pharmaceutical companies, and industry partners at this year’s symposium.

Biologics Capabilities Built for the Antibody Industry

The antibody landscape demands manufacturing partners who understand the complexity of biologic drug products β€” from formulation development and clinical supply through to commercial-scale production. Adragos Pharma offers a strong European footprint with GMP-certified facilities purpose-built for sterile and aseptic manufacturing:

βœ” Aseptic fill-and-finish for biologics and small molecules β€” liquid and lyophilised vials for clinical trial and commercial supply (Jura, Switzerland)
βœ” Prefilled syringes, liquid and lyophilised vials β€” advanced aseptic filling, freeze-drying, and inspection systems (Maisons-Alfort, France)
βœ” End-to-end CDMO services β€” from drug development and tech transfer to lifecycle management and commercial manufacturing
βœ” Regulatory-ready, scalable processes β€” designed for the quality and compliance standards the biologics sector requires

Why Partner with Adragos Pharma for Antibody Manufacturing?

At Adragos Pharma, we combine multinational operational strength with personalised service. Our 7 GMP facilities across the EU, US, and Japan allow us to offer local insights and tailored solutions β€” because we know that one size does not fit all. From early-stage clinical supply through to full-scale commercial production, we invest in the success of your product beyond standard timelines.

Our established presence in Japan β€” the world’s most demanding pharmaceutical market β€” reflects our commitment to quality, adaptability, and long-term partnership.

Person

Nancy Martinez
Senior Business Development Manager

Nancy brings a strong scientific background in biologics, CDMO services, and clinical project management to every conversation. With previous key roles at GTP Bioways and Pierre Fabre, she has supported innovative biotech and pharma projects across Europe. Her expertise spans antibody development, aseptic fill & finish, client relationship management, and strategic sales β€” offering a unique combination of technical insight and commercial acumen to partners in the life sciences industry.

About the 14th Antibody Industrial Symposium (AIS2026)

The Antibody Industrial Symposium, organised by MabDesign and MabImprove, is one of the premier European events dedicated to the antibody and therapeutic protein industry. AIS2026 brings together researchers, CDMOs, biotech companies, and pharmaceutical leaders for scientific presentations, partnering sessions, and networking β€” all focused on advancing the antibody sector from discovery to patient.

Connect with Us in Montpellier

Our team will be attending AIS2026 in Montpellier, and we welcome the opportunity to discuss your biologics manufacturing needs, explore potential collaborations, and share how Adragos Pharma can support your antibody pipeline β€” from clinical-stage fill-and-finish through to commercial supply.

πŸ“… June 30- July 1st
πŸ“ Montpellier, France

We look forward to meeting you and exploring new opportunities to advance antibody development and manufacturing together.

]]>
https://adragos-pharma.com/adragos-pharma-at-the-14th-antibody-industrial-symposium-ais2026-montpellier-france/feed/ 0
Adragos Pharma at BOS Basel 2026 https://adragos-pharma.com/biotech-outsourcing-strategies-bos-basel-2026/ https://adragos-pharma.com/biotech-outsourcing-strategies-bos-basel-2026/#respond Tue, 26 May 2026 12:51:11 +0000 https://adragos-pharma.com/?p=25405 Adragos Pharma is pleased to announce its participation in Biotech Outsourcing Strategies (BOS) Basel 2026, taking place in Basel, Switzerland, from June 30 to July 1. As a global Contract Development and Manufacturing Organisation (CDMO), we look forward to connecting with industry leaders, biotech innovators, and potential partners to discuss how our integrated capabilities can support pharmaceutical development, manufacturing, and commercialisation.

Why Meet Adragos Pharma at BOS Basel?

Biotech Outsourcing Strategies Basel is one of the leading events for biotech and pharmaceutical outsourcing, partnering, and business development. As a trusted CDMO with a growing European footprint, Adragos Pharma is committed to delivering:

βœ” End-to-end CDMO solutions β€” from drug development through to commercial manufacturing across 7 GMP-certified facilities in the EU, US, and Japan
βœ” Aseptic fill and finish β€” liquid and lyophilised vials, prefilled syringes, and advanced freeze-drying for small molecules and biological products at our Jura and Maisons-Alfort sites
βœ” Drug development expertise β€” formulation and analytical development for oral, parenteral, and topical dosage forms, including HPAPI handling, at our Athens centre with over 25 years of experience and more than 150 molecules developed
βœ” Early-phase to commercial scale β€” clinical trial material supply, technology transfer, lifecycle management, and regulatory compliance to accompany your product throughout its entire journey

Our Commitment to Partnership

We combine multinational operational strength with personalised service. Our approach is built on co-ownership of your product’s success β€” from tech transfer to lifecycle management, we invest beyond standard timelines. Our established presence in Japan, the world’s most demanding market, demonstrates our adaptability, commitment to quality, and long-term vision.

Meet Our Team at BOS Basel 2026

Our experienced team of business development and strategic project leaders will be attending throughout the event. We invite you to connect and explore how Adragos Pharma can support your next project.

Person

Sofiane Borsla
Business Development Manager

Sofiane brings extensive experience in business development, market access, and commercial strategy across the pharmaceutical and biotech sectors. With a Master’s in Chemistry and an MBA in Biotechnology & Pharmaceutical Management, he identifies and pursues new business opportunities, combining technical expertise with strategic commercial insight to drive business expansion at Adragos Pharma.

Person

Barbara Ruggiero
Business Development Director

Barbara brings more than 20 years of experience in the pharmaceutical industry with deep expertise in pharmaceutical services sales. At Adragos Pharma, she focuses on fill and finish services for early-phase projects at our Jura and Maisons-Alfort sites, supporting customers throughout the entire development of their product for both small molecules and biological products.

Person

Marie-Sophie Quittet
Head of Strategic Projects, Jura

Marie-Sophie holds both a Doctor of Pharmacy (PharmD) and a Doctor of Philosophy (PhD), showcasing her expertise in the pharmaceutical industry. With over a decade of experience spearheading clinical production projects in Europe and the US, she brings strategic leadership in implementing clinical and commercial projects at our Jura facility.

Connect with Us in Basel

Our team will be attending Biotech Outsourcing Strategies (BOS) Basel 2026, and we welcome the opportunity to engage in discussions on potential collaborations, outsourcing solutions, and strategic partnerships. If you are attending, we invite you to connect with us during the event.

πŸ“… June 30 – July 1, 2026
πŸ“ Basel, Switzerland

We look forward to productive discussions and new opportunities to drive innovation in pharmaceutical development and manufacturing.

]]>
https://adragos-pharma.com/biotech-outsourcing-strategies-bos-basel-2026/feed/ 0
Webinar: De-Risking Sterile Fill-Finish from Clinical to Commercial | Adragos Pharma https://adragos-pharma.com/webinars-de-risking-sterile-fill-finish-clinical-commercial/ https://adragos-pharma.com/webinars-de-risking-sterile-fill-finish-clinical-commercial/#respond Mon, 18 May 2026 11:55:32 +0000 https://adragos-pharma.com/?p=25124

● Live Webinar  Β·  25 June 2026

De-Risking Sterile Fill-Finish from Clinical to Commercial

How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success.

Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, technology transfer, quality expectations and supply continuity all need the right technical and operational support. Join Adragos Pharma for a practical webinar designed for CMC, outsourcing, MSAT, technical operations and external manufacturing teams looking to reduce risk across the sterile product lifecycle.

πŸ“…  Date: Thursday, 25 June 2026

πŸ•’  Time: 4PM CET  /  10AM EST

πŸ’»  Format: Live webinar β€” Free to attend

Is this your programme?

This webinar is designed for teams working on sterile products where timelines, quality and supply reliability matter. It is especially relevant for:

  • CMC and pharmaceutical development teams
  • Outsourcing and external manufacturing leaders
  • MSAT and technical operations teams
  • Sterile manufacturing and fill-finish leads
  • Technology transfer and industrialisation teams
  • Procurement and supply chain decision-makers
  • Project and programme managers supporting clinical-to-commercial progression

The Challenge

Sterile manufacturing is where complexity becomes operational

Bringing sterile products to market requires more than capacity. Each stage introduces potential risk: process transfer, scale-up, lyophilisation, aseptic control, inspection, packaging and commercial supply planning.

πŸ”

Process Transfer Risk

Delays are not always caused by the science. Unclear transfer models and insufficient CDMO flexibility create execution challenges that slow programmes down.

❄

Lyophilisation Complexity

Scale-up from clinical to commercial demands deep technical expertise, robust cycle development and rigorous qualification β€” up to ~70,000 vials per batch.

🏭

Aseptic Control at Scale

Aseptic manufacturing requires consistent quality governance, controlled environments, RABS technology, audit readiness and compliant fill-finish execution.

πŸ“¦

Supply Continuity

Manufacturing partners must support the full journey β€” from clinical development to commercial supply β€” with flexibility and long-term operational commitment.

πŸ“‹

Regulatory CMC Readiness

CMC submissions, stability studies, analytical validation and multi-authority compliance add significant complexity across every product stage.

🌐

Clinical-to-Commercial Continuity

Bridging clinical batches to commercial supply requires an integrated CDMO partner with depth across dosage forms β€” not disconnected service modules.

The right CDMO partner can help reduce these risks by combining technical depth, quality-driven execution and a network able to adapt as your product needs evolve β€” from first GMP batch to high-volume commercial supply.



Practical insights to help reduce programme risk

During the webinar, Adragos Pharma experts will share how an integrated sterile CDMO model can support customers across key stages of the product lifecycle. You will learn how to:

  • Identify what to look for in a sterile fill-finish CDMO partner
  • Reduce technical risk during lyophilisation qualification and scale-up
  • Improve speed and consistency through structured technology transfer
  • Integrate products into sterile manufacturing facilities with a clear execution model
  • Use a flexible sterile network to support clinical-to-commercial supply



Two practical case studies

Real-world examples of how Adragos Pharma experts approach sterile programme challenges, from qualification through to commercial execution.

Lyophilisation Qualification and Scale-Up

Learn how lyophilisation performance, product temperature mapping, sublimation behaviour and process robustness can be assessed to support scale-up from clinical to commercial manufacturing.

Product Integration into a Sterile Manufacturing Facility

Explore how a structured, site-independent approach to technology transfer can support faster, more consistent product integration across a CDMO network.

Adragos Pharma’s sterile manufacturing network combines aseptic fill-finish, lyophilisation, inspection, packaging and quality-driven execution across multiple sites.

Our sterile capabilities include prefilled syringes, liquid and lyophilised vials, ampoules, inspection, packaging and commercial manufacturing support. The Sterile Cluster brochure positions Adragos as a global integrated partner from clinical manufacturing to high-volume global supply.

With Maisons-Alfort and Jura as key sterile sites, Adragos Pharma is strengthening its ability to support customers with both commercial-scale execution and clinical-to-commercial flexibility.

Batch sizes from 30 to 1,500 L
Aseptic filling or terminal sterilisation process by heat

⟢

Clinical and small-scale commercial manufacturing
Sterile liquids, suspension, emulsion, viscous liquids and lyophilised
Glass vials size: 2R, 6R, 10R, 20R, 30R​

⟢

Manufacturing of PFS and vials supported by CIP/SIP and active RABS technologies.

PFS: 0,5 mL and 1 mL
Vials: 6R, 10R, 7 mL, 10 mL, 15 mL, 22 mL

⟢

Meet Our Speakers

Highly skilled and well-trained scientists focused on development.

Paul Marnat

Head of Tech Transfer, Maisons-Alfort

Paul Marnat is a pharmacist with more than 12 years of leadership experience in sterile pharmaceutical manufacturing, specialising in aseptic operations, GMP compliance, and technology transfer. Over the course of his career, he has held key manufacturing leadership roles across several Sanofi injectable manufacturing sites, overseeing operations and delivering complex industrial projects, including aseptic process transfers and product launches. Following the 2026 acquisition of Sanofi’s Maisons-Alfort injectable manufacturing site by Adragos Pharma, Paul has served as Head of Customer Service & Tech Transfer at Adragos Pharma. He now leads customer-facing activities and technology transfer programmes, partnering closely with internal teams to deliver efficient product transfers and dependable fill-finish operations.

Paul Marnat

Guillaume Mollandin

Head of Engineering and PMO, Jura

Guillaume Mollandin is a microbiology engineer with more than 14 years of progressive leadership in pharmaceutical manufacturing and project management. He began his career advancing from Manufacturing Manager in aseptic filling and visual inspection to Head of Packaging Operations. In 2020 he joined another company as Head of Fill-Finish Operations. From 2021 to 2023 he led aseptic fill-finish process development and served as MSAT Head for a DPS growth project. Since November 2024, Guillaume has been Head of Engineering & Project Management (PMO) at Adragos Pharma’s Jura site, spearheading flexible, customer-focused fill-finish solutions.

Guillaume Mollandin

Tobias SchlΓΆgl

Business Development Director

Tobias joined Adragos Pharma in February 2026 as Business Development Director and brings 20 years of experience in the pharmaceutical industry with profound know-how in sterile drug product manufacturing and pharmaceutical services. Working several years for Vetter Pharma, he held various positions including Quality Assurance, Project Management and, most recently, as a Business Development Manager. In addition, he was several years Head of Drug Product Manufacturing aseptic production at Boehringer Ingelheim. At Adragos Pharma, Tobias is focusing on fill & finish services. In his role he also supports the sales and marketing team and helps broaden the expertise and network for small molecules and biologic products. He contributes with his understanding of production and quality, combined with the ability to translate complex technical topics into value-added solutions for partners and stakeholders.

Tobias SchlΓΆgl
]]>
https://adragos-pharma.com/webinars-de-risking-sterile-fill-finish-clinical-commercial/feed/ 0
Adragos Pharma to DCAT Week 2026 [23th-26th March] https://adragos-pharma.com/adragos-pharma-to-dcat-week-2026-23th-26th-march/ https://adragos-pharma.com/adragos-pharma-to-dcat-week-2026-23th-26th-march/#respond Tue, 03 Mar 2026 08:19:55 +0000 https://adragos-pharma.com/?p=23759 Adragos Pharma is pleased to announce its participation in DCAT Week 2026, taking place in New York City from March 23-26th. As a global Contract Development and Manufacturing Organization (CDMO), we look forward to engaging with industry leaders, partners, and stakeholders to discuss the latest advancements and opportunities in pharmaceutical manufacturing and supply chain management.

Our Commitment to Excellence in CDMO Services

DCAT Week is a key event for the pharmaceutical and biopharmaceutical industries, offering a unique platform for business development and strategic networking. Adragos Pharma remains committed to delivering high-quality, cost-effective pharmaceutical manufacturing and development solutions, ensuring operational efficiency and regulatory compliance for our partners worldwide.

Our team will be available to discuss:
βœ” Comprehensive CDMO services, including drug development and commercial manufacturing
βœ” Innovative solutions for improving supply chain efficiency and production scalability
βœ” Opportunities for collaboration to enhance pharmaceutical development and market access
βœ” Our dedication to quality, sustainability, and operational excellence

Meet Our Team at DCAT Week 2026

We are delighted to share that Henny Zijlstra, Chief Commercial Officer (CCO), and Dr. Andreas Raabe, Chief Executive Officer (CEO), will be available for discussions during the event.

Dr. Andreas Raabe, Chief Executive Officer (CEO)

Dr. Andreas Raabe is the founder of Adragos Pharma, with a strong scientific and strategic background in global pharmaceuticals. His leadership focuses on operational excellence, supply chain optimization, and building a world-class CDMO.

Henny Zijlstra, Chief Commercial Officer (CCO)

Henny Zijlstra brings extensive expertise in pharmaceutical manufacturing and business development. She is dedicated to fostering strong client partnerships and driving innovative, customer-centric solutions in the CDMO space.

Connect with Us in New York

We welcome the opportunity to connect with industry professionals attending DCAT Week 2026. To arrange a meeting, please contact us in advance to schedule a discussion at a convenient time.

πŸ“… March 23–26, 2026
πŸ“ New York City

We look forward to productive discussions and the opportunity to strengthen partnerships that drive innovation in pharmaceutical manufacturing.

]]>
https://adragos-pharma.com/adragos-pharma-to-dcat-week-2026-23th-26th-march/feed/ 0
Adragos Pharma at Bio-Europe 2025 in Vienna https://adragos-pharma.com/adragos-pharma-at-bio-europe-2025-in-vienna/ https://adragos-pharma.com/adragos-pharma-at-bio-europe-2025-in-vienna/#respond Fri, 25 Jul 2025 11:53:46 +0000 https://adragos-pharma.com/?p=21321 Adragos Pharma is pleased to announce its participation in Bio-Europe 2025, taking place in Vienna, Austria, from November 3 to 5. As a global Contract Development and Manufacturing Organization (CDMO), we look forward to connecting with industry leaders, partners, and innovators to discuss the future of pharmaceutical development, manufacturing, and commercialization.

Our Commitment to Pharmaceutical Innovation

Bio-Europe 2025 serves as a leading platform for partnering, business development, and networking in the biopharmaceutical and life sciences industries. As a trusted CDMO, Adragos Pharma remains dedicated to delivering:

βœ” Comprehensive CDMO solutions for pharmaceutical development and manufacturing
βœ” Innovative approaches to supply chain and operational excellence
βœ” Collaborative opportunities to accelerate market entry and expansion
βœ” A strong commitment to quality, sustainability, and regulatory compliance

Person

Marie-Sophie Quittet
Head of Strategic Projects, Jura

Marie-Sophie holds both a Doctor of Pharmacy (PharmD) and a Doctor of Philosophy (PhD), showcasing her expertise in the pharmaceutical industry. As Head of Strategic Projects, she has over a decade of experience, spearheading clinical production projects in Europe and the US.

Person

Sofiane Borsla
Business Development Manager

Connect with Us in Vienna

Our team will be attending Bio-Europe 2025, and we welcome the opportunity to engage in discussions on potential collaborations, market insights, and strategic partnerships. If you are attending, we invite you to connect with us during the event.

πŸ“… November 3–5, 2025
πŸ“ Vienna, Austria

We look forward to productive discussions and new opportunities to drive innovation in pharmaceutical manufacturing and development.

]]>
https://adragos-pharma.com/adragos-pharma-at-bio-europe-2025-in-vienna/feed/ 0
Adragos at CPHI WW, Frankfurt 2025 https://adragos-pharma.com/adragos-at-cphi-frankfurt-2025/ https://adragos-pharma.com/adragos-at-cphi-frankfurt-2025/#respond Tue, 01 Jul 2025 07:40:35 +0000 https://adragos-pharma.com/?p=18922

CPHI (Convention on Pharmaceutical Ingredients) is the leading global gathering for the pharmaceutical industry. It brings together research, development and manufacturing experts to forge partnerships that drive new therapies and innovations for patients everywhere. Covering the full supply chain, from raw materials to finished products. CPHI offers a unique platform for making vital connections and exploring the latest trends, technologies and challenges.

This year, Adragos is excited to return to CPHI. We invite you to connect with us at the event!

πŸ“… Date: 28th-30th October 2025
πŸ“Location: Messe Frankfurt
Booth Number: #5.0C50

Run With Adragos!

This year we will be hosting a run during our participation at CPHI! Whether you prefer to sprint, jog or take a leisurely walk, everyone is welcome to join us. It is the perfect opportunity to stretch your legs before a busy day.
Register below for more details.
#runwithshiro

πŸ“… Date: 29th October 2025 at 8:00 am
πŸ“Location: GrΓΌneburgpark, Frankfurt, Germany

image of shiro for Adragos run for cphi

A Full-Theme German Evening!

This is a private event where you can enjoy an apple wine tasting, a delectable appetizer tour, and a classic German dinner for an authentic culinary experience!

Would you like to participate?
Visit us at our booth at CPHI and ask for more information!

About Last Year CPHI In Milan

]]>
https://adragos-pharma.com/adragos-at-cphi-frankfurt-2025/feed/ 0
Empowering Women In Pharma [10th July 2025] https://adragos-pharma.com/empowering-women-in-pharma-10th-july-2025/ https://adragos-pharma.com/empowering-women-in-pharma-10th-july-2025/#respond Mon, 30 Jun 2025 10:05:14 +0000 https://adragos-pharma.com/?p=19176 In today’s fast-evolving healthcare sector, women are playing a crucial role in shaping the future of pharmaceuticals. Therefore, we decided to recognize and amplify the contributions of women in the pharmaceutical industry, offering a platform for women to connect, learn, and inspire, through our event “Empowering Women in Pharma”.

Interphex Week Special Lecture 2
πŸ“… Date: Thursday, July 10, 2025|15:00 ο½ž16:00
πŸ“Location: Big Sight Tokyo, Japan [Venue A East Hall]

About The Event

​Interphex Tokyo is approaching, and we are excited to announce a special seminar hosted by our Chief Commercial Officer, Henny Zijlstra, and Head of US & APAC, Hideyuki Tanaka.

The seminar will explore the unique challenges women encounter in both Japan and Western countries in the pharmaceutical industry, highlight the critical importance of supporting female leadership in pharma, and share personal hopes and visions for the future of women’s empowerment.

one female scientists work in laboratories

Why You Should Attend

This event is the perfect fit for you if you are interested in hearing a discussion form different perpectives about how we can all do our part in empowering women and why women empowerment is crucial in our industry!

Whether you are a experienced leader or just starting your career in the industry we are inviting you to join this seminar!

Our Key Speakers

We are honored to welcome our expert speakers, Henny Zijlstra and Hideyuki Tanaka from Adragos Pharma, who will share their insights and experiences on empowering women, promoting diversity, and driving innovation in the pharmaceutical industry at our “Women in Pharma” event in Tokyo.

Henny Zijlstra, Chief Commercial Officer (CCO)

Image of Henny Zijlstra, the Chief commercial officer at Adragos Pharma

Meet Henny, our esteemed Chief Commercial Officer (CCO) at Adragos Pharma. Henny leads with a customer-first approach, driving our mission to deliver superior experiences and outcomes. With extensive experience in the pharmaceutical CDMO industry, she disrupts the market with innovative strategies that fuel progress and innovation. Passionate about promoting diversity and inclusion, Henny actively serves as a role model for the next generation of female leaders. Her leadership raises the bar, inspiring our team to exceed expectations while fostering deep connections with customers.

Hideyuki Tanaka, Head of Commercial US & APAC

Image of Hideyuki

Hide serves as Adragos’ Head Commercial US & APAC and brings over two decades of experience within the pharmaceutical and CDMO industry. He has an extensive global background spanning the United States, Europe, and Japan. Throughout Hide’s career, he has excelled in roles covering sales, marketing, business development, corporate governance, project management, and medicinal chemistry.  Possessing a Master’s in Pharmaceutical Chemistry and an MBA from Bond University in Australia, Hide exemplifies an unwavering commitment to professional growth.

]]>
https://adragos-pharma.com/empowering-women-in-pharma-10th-july-2025/feed/ 0
Adragos Pharma goes to Interphex 2025 in Tokyo [9th-11th July] https://adragos-pharma.com/adragos-pharma-goes-at-interphex-2025-tokyo-9-11-july/ https://adragos-pharma.com/adragos-pharma-goes-at-interphex-2025-tokyo-9-11-july/#respond Wed, 14 May 2025 15:16:23 +0000 https://adragos-pharma.com/?p=17632 Adragos Pharma is pleased to announce its participation in Interphex 2025, taking place in Tokyo, Japan, from July 9-11. As a global Contract Development and Manufacturing Organization (CDMO), we look forward to connecting with industry leaders, partners, and innovators to discuss the future of pharmaceutical development, manufacturing, and commercialization.

πŸ“…Date: July 9-11, 2025
πŸ“Location: Big Sight, Tokyo, Japan

Booth Number: #W2-40

Our Commitment to Pharmaceutical Innovation

Interphex is a premier event for showcasing innovation, technology, and collaboration in the pharmaceutical and bioprocessing sectors. Adragos Pharma will take part to this event, where a team of local experts offer deep regulatory knowledge, technical expertise, and experience tailored to both Japanese and non-Japanese pharmaceutical companies.

We are committed to:

βœ” Providing seamless CDMO solutions for pharmaceutical development, manufacturing, and packaging that meet Japanese quality and regulatory standards
βœ” Guiding non-Japanese companies through every step of Japanese market entryβ€”from registration to commercialization
βœ” Supporting Japanese companies with innovative strategies for operational excellence and supply chain optimization
βœ” Ensuring a smooth, compliant, and efficient path to success in Japan’s dynamic pharmaceutical landscape

Visit us at INTERPHEX to discover how our Kawagoe facility and expert team can help you navigate and thrive in the Japanese market.

Meet Our Team at Interphex 2025

We are delighted to share that Henny Zijlstra (Chief Commercial Officer), Masanori Kurogome (Site Head), Hideyuki Tanaka (Head of Commercial US & APAC), and Munetaka Hirosaki (Customer Relationship Manager) will be available for discussions during the event.

Henny Zijlstra, Chief Commercial Officer (CCO)

Henny Zijlstra brings extensive expertise in pharmaceutical manufacturing and business development. She is dedicated to fostering strong client partnerships and driving innovative, customer-centric solutions in the CDMO space.

Masanori Kurogome, Site Head (Kawagoe)

Masanori holds a pharmacy degree with a focus on analytical chemistry. His experience in production broadened his expertise. In 2018, he started programming to expand his skill set. Kurogome is committed to making Adragos Kawagoe an irreplaceable site.

Hideyuki Tanaka, Head of Commercial US & APAC

Hide serves as Adragos’ Head Commercial US & APAC and brings over two decades of experience within the pharmaceutical and CDMO industry. He has an extensive global background spanning the United States, Europe, and Japan.

Munetaka Hirosaki, Customer Relationship Manager (Kawagoe)

Munetaka has extensive experience in supply chain management, production, and operational excellence. Previously at Sanofi, he specializes in business development, order management, and strategic customer relations in the pharmaceutical industry.

Connect with Us in Tokyo

Our team will be attending Interphex 2025, and we welcome the opportunity to engage in discussions on potential collaborations, market insights, and strategic partnerships. If you are attending, we invite you to connect with us during the event.

πŸ“… July 9-11, 2025
πŸ“ Big Sight, Tokyo, Japan

Booth Number: #W2-40

We look forward to productive discussions and new opportunities to drive innovation in pharmaceutical manufacturing and development.

]]>
https://adragos-pharma.com/adragos-pharma-goes-at-interphex-2025-tokyo-9-11-july/feed/ 0